The Atlantic correctly identifies the shift from pill-popping to self-injection but underplays how GLP-1 agonists and unregulated peptides now restructure economic and temporal realities for millions. In 2025, 12 percent of U.S. adults using these drugs report monthly costs exceeding $1,000 out-of-pocket, forcing trade-offs in housing and childcare that earlier generations faced only with chronic illness. This extends beyond obesity treatment into longevity protocols, where users combine semaglutide with BPC-157 or tesamorelin, creating layered injection schedules that demand daily planning once reserved for diabetics. The original coverage notes needlephobia statistics yet misses the rapid desensitization effect: medical-spa chains like JECT have normalized 2,400 micro-injections per session, turning aversion into a subscription service. Broader patterns reveal a convergence with IVF hormone regimens and cosmetic fillers, all converging on the same supply chains and regulatory gray zones. RFK Jr.’s public peptide endorsements accelerate this by signaling policy tolerance, yet overlook emerging data on muscle-loss rebound and gastrointestinal dependency that appear within three to six months. A 2024 JAMA study documented that 40 percent of GLP-1 users alter exercise and meal timing around injection days, embedding pharmacological rhythm into ordinary life. Meanwhile, an NEJM analysis of peptide compounding pharmacies shows uneven purity standards that the Atlantic framing treats as fringe rather than mainstream supply. The result is not merely more needles but a new bodily baseline where physical capacity is leased monthly rather than owned outright.